Literature DB >> 29601052

The role of neoadjuvant chemoradiotherapy in multimodality treatment of esophageal or gastroesophageal junction cancer.

Fredrik Klevebro1, Magnus Nilsson1.   

Abstract

Entities:  

Year:  2018        PMID： 29601052      PMCID： PMC5863166          DOI： 10.21037/jtd.2017.11.139

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Ralf D Hofheinz; Claudia Pauligk; Hans-Georg Kopp; Georg Martin Haag; Kim Barbara Luley; Johannes Meiler; Nils Homann; Sylvie Lorenzen; Harald Schmalenberg; Stephan Probst; Michael Koenigsmann; Matthias Egger; Nicole Prasnikar; Karel Caca; Jörg Trojan; Uwe M Martens; Andreas Block; Wolfgang Fischbach; Rolf Mahlberg; Michael Clemens; Gerald Illerhaus; Katja Zirlik; Dirk M Behringer; Wolff Schmiegel; Michael Pohl; Michael Heike; Ulrich Ronellenfitsch; Martin Schuler; Wolf O Bechstein; Alfred Königsrainer; Timo Gaiser; Peter Schirmacher; Wael Hozaeel; Alexander Reichart; Thorsten O Goetze; Mark Sievert; Elke Jäger; Stefan Mönig; Andrea Tannapfel
Journal:  Lancet Oncol       Date:  2016-10-22       Impact factor: 41.316

2.  Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.

Authors:  Bryan H Burmeister; Janine M Thomas; Elizabeth A Burmeister; Euan T Walpole; Jennifer A Harvey; Damien B Thomson; Andrew P Barbour; David C Gotley; B Mark Smithers
Journal:  Eur J Cancer       Date:  2011-02       Impact factor: 9.162

3.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.

Authors:  Michael Stahl; Martin K Walz; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Jorge Riera-Knorrenschild; Peter Langer; Rita Engenhart-Cabillic; Michael Bitzer; Alfred Königsrainer; Wilfried Budach; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

4.  Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.

Authors:  F Klevebro; M Lindblad; J Johansson; L Lundell; M Nilsson
Journal:  Br J Surg       Date:  2016-09-30       Impact factor: 6.939

5.  A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.

Authors:  F Klevebro; G Alexandersson von Döbeln; N Wang; G Johnsen; A-B Jacobsen; S Friesland; I Hatlevoll; N I Glenjen; P Lind; J A Tsai; L Lundell; M Nilsson
Journal:  Ann Oncol       Date:  2016-01-17       Impact factor: 32.976

6.  TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).

Authors:  Trevor Leong; B Mark Smithers; Michael Michael; Val Gebski; Alex Boussioutas; Danielle Miller; John Simes; John Zalcberg; Karin Haustermans; Florian Lordick; Christoph Schuhmacher; Carol Swallow; Gail Darling; Rebecca Wong
Journal:  BMC Cancer       Date:  2015-07-21       Impact factor: 4.430

7.  Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.

Authors:  Bo Jan Noordman; Joel Shapiro; Manon Cw Spaander; Kausilia K Krishnadath; Hanneke Wm van Laarhoven; Mark I van Berge Henegouwen; Grard Ap Nieuwenhuijzen; Richard van Hillegersberg; Meindert N Sosef; Ewout W Steyerberg; Bas Pl Wijnhoven; J Jan B van Lanschot
Journal:  JMIR Res Protoc       Date:  2015-06-29

8.  ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

Authors:  Jens Hoeppner; Florian Lordick; Thomas Brunner; Torben Glatz; Peter Bronsert; Nadine Röthling; Claudia Schmoor; Dietmar Lorenz; Christian Ell; Ulrich T Hopt; J Rüdiger Siewert
Journal:  BMC Cancer       Date:  2016-07-19       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.